
Saturday, June 28, 2025 5:50:10 PM
Those topline 371 results for Schizo could destroy many shorts even before 273 approval finishes the job.
Delusions. This is when people believe in things that aren't real or true. For example, people with schizophrenia could think that they're being harmed or harassed when they aren't. They could think that they're the target for certain gestures or comments when they aren't. They may think they're very famous or have great ability when that's not the case. Or they could feel that a major disaster is about to occur when that's not true. Most people with schizophrenia have delusions.
Hallucinations. These usually involve seeing or hearing things that other people don't observe. For people with schizophrenia, these things seem real. Hallucinations can occur with any of the senses, but hearing voices is most common.
Disorganized speech and thinking. Disorganized speech causes disorganized thinking. It can be hard for people with schizophrenia to talk with other people. The answers people with schizophrenia give to questions may not be related to what's being asked. Or questions may not be answered fully. Rarely, speech may include putting together unrelated words in a way that can't be understood. Sometimes this is called word salad.
Extremely disorganized or unusual motor behavior. This may show in several ways, from childlike silliness to being agitated for no reason. Behavior isn't focused on a goal, so it's hard to do tasks. People with schizophrenia may not want to follow instructions. They may move in ways that are not typical or not appropriate to the social setting. Or they may not move much or respond at all.
Negative symptoms. People with schizophrenia may not be able to function in the way they could before their illness started. For example, they may not bathe, make eye contact or show emotions. They may speak in a monotone voice and not be able to feel pleasure. Also, they may lose interest in everyday activities, socially withdraw and have a hard time planning ahead.
Two important considerations.
First, how subtle might Anavex 3-71's results be? Easy for anyone to see; or slight and questionable?
Secondly, how long might it take for Anavex 3-71 work: days, weeks, or months?
Simply, results will be clearly visible to all; patients and others. The list of symptoms will simply be gone or so reduced that everyone will instantly be happy.
I find no indications, in murine (lab-animal) tests, that Anavex 3-71's mechanisms of action (MOAs) will require lengthy periods to be effective. Results should appear promptly.
Let’s see if the clinical results fit these perspectives. If so, the massive population of schizophrenia patients will be enthused. The stories should proliferate, resulting in prompt FDA approval.
Recent AVXL News
- Form 8-K - Current report • Edgar (US Regulatory) • 07/03/2025 09:25:40 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/13/2025 09:30:36 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/09/2025 09:30:47 PM
- Anavex Life Sciences to Participate at Upcoming Healthcare Conferences • GlobeNewswire Inc. • 05/14/2025 11:30:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/13/2025 08:31:17 PM
- Anavex Life Sciences Reports Fiscal 2025 Second Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 05/13/2025 11:30:00 AM
- Anavex Life Sciences to Announce Fiscal 2025 Second Quarter Financial Results on Tuesday, May 13, 2025 • GlobeNewswire Inc. • 05/06/2025 11:30:00 AM
- Anavex Life Sciences Announces Full Enrollment of Phase 2 Study of ANAVEX®3-71 for the Treatment of Schizophrenia • GlobeNewswire Inc. • 05/01/2025 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/01/2025 12:00:38 AM
- Anavex Life Sciences to Participate in The Citizens Life Sciences Conference • GlobeNewswire Inc. • 04/30/2025 11:30:00 AM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/25/2025 08:40:36 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/25/2025 08:35:45 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/25/2025 08:31:01 PM
- Anavex Life Sciences Announces Appointment of Dr. Audrey Gabelle, MD, PhD to the Scientific Advisory Board • GlobeNewswire Inc. • 04/23/2025 11:30:00 AM
- Anavex Life Sciences Announces Presentation at 9th International Conference on Alzheimer’s Disease and Related Disorders in the Middle East • GlobeNewswire Inc. • 04/21/2025 11:30:00 AM
- Anavex Life Sciences Announces Positive up to 4-Years Oral Blarcamesine Results from Phase IIb/III Open-Label Extension Trial in Early Alzheimer’s Disease • GlobeNewswire Inc. • 04/05/2025 03:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/03/2025 01:46:45 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/03/2025 01:46:27 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/03/2025 01:45:40 AM
- Anavex Life Sciences to Present at the 24th Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 03/31/2025 11:30:00 AM
- Anavex Life Sciences to Present at the 45th Annual TD Cowen Health Care Conference • GlobeNewswire Inc. • 02/24/2025 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/12/2025 02:06:26 PM
- Anavex Life Sciences Reports Fiscal 2025 First Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 02/12/2025 12:30:00 PM
- Anavex Life Sciences to Announce Fiscal 2025 First Quarter Financial Results on Wednesday, February 12, 2025 • GlobeNewswire Inc. • 02/05/2025 12:30:00 PM
- Anavex Life Sciences Announces Issuance of Blarcamesine (ANAVEX®2-73) Composition of Matter U.S. Patent Expanding its Intellectual Property Portfolio • GlobeNewswire Inc. • 01/27/2025 12:30:00 PM
Precision Genetic Medicine Platform Could Disrupt Standard of Care in Metastatic Cancer, Other Indications of Unmet Needs • CLDI • Jul 7, 2025 9:00 AM
VAYK Discloses More Insider Buying Approaching 15 Million • VAYK • Jul 2, 2025 10:37 AM
Patented, Groundbreaking Blockchain for Public Companies 'BlackStar Digital Trading PlatformTM' can Facilitate U.S. Registered Securities to Trade on Blockchain Without Tokens. • BEGI • Jul 1, 2025 12:54 PM
UC Asset (UCASU) Public Offering's Acquisition Target Reported Better Results • UCASU • Jul 1, 2025 9:15 AM
One World Products, Inc. Appoints William Rowland as Chief Financial Officer • OWPC • Jul 1, 2025 9:14 AM
Envirotech Begins Delivery of Bumble Bee Electric School Bus Units with First Three Texas Orders • EVTV • Jul 1, 2025 9:01 AM